X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Endeavor has acquired exclusive worldwide rights to Hummingbird Bio’s HMBD-501, a next-generation HER3-targeted antibody-drug conjugate (ADC).
Lead Product(s): HMBD-501
Therapeutic Area: Oncology Product Name: HMBD-501
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Endeavor Biomedicines
Deal Size: $430.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 19, 2023
Details:
Under the collaboration, Hummingbird will evaluate its potentially best-in-class HER3-targeting antibody, HMBD-001, in combination with SoC chemotherapy with or without Merck's cetuximab, anti-EGFR mAb, in patients with sqNSCLC in a Phase 1b clinical trial.
Lead Product(s): HMBD-001,Cetuximab
Therapeutic Area: Oncology Product Name: HMBD-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 15, 2023
Details:
George Clinical will provide its full-service CRO expertise for the Hummingbird sponsored trials, including HMBD-001, a unique antibody engineered to bind strongly and specifically to the dimerization interface of HER3, developed with its Rational Antibody Discovery platform.
Lead Product(s): HMBD-001
Therapeutic Area: Oncology Product Name: HMBD-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: George Clinical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 04, 2023
Details:
HMBD-001 is an anti-HER3 antibody in development that has the potential to fully block both ligand-dependent and independent HER3 activation and oncogenic signaling, by targeting a key epitope located at the interface where HER3 forms heterodimers with HER2 or EGFR.
Lead Product(s): HMBD-001
Therapeutic Area: Oncology Product Name: HMBD-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
Under the terms of the agreement, Hummingbird Bio is granted rights to utilize Synaffix proprietary Antibody-Drug Conjugate (ADC) technologies GlycoConnect™ and HydraSpace™, in combination with select toxSYN™ linker-payloads.
Lead Product(s): Antibody-drug Conjugate-based Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Synaffix
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 04, 2023
Details:
HMBD-002 is an investigational IgG4 anti-VISTA antagonist antibody to target the region where VISTA interacts with binding partners that have been shown to play an important role in modulating T cell activity, potentially unlocking the immune system to attack cancer cells.
Lead Product(s): HMBD-002,Pembrolizumab
Therapeutic Area: Oncology Product Name: HMBD-002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
Under this collaboration, Hummingbird will evaluate the safety, tolerability, and anti-tumor activity of its novel anti-VISTA antibody, HMBD-002, in combination with KEYTRUDA ® (pembrolizumab).
Lead Product(s): HMBD-002,Pembrolizumab
Therapeutic Area: Oncology Product Name: HMBD-002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 25, 2021
Details:
HMBD-001 is a novel antibody with a unique, differentiated mechanism of action that fully inhibits HER3 activation of the MAPK/PI3K tumor growth signaling pathway.
Lead Product(s): HMBD-001
Therapeutic Area: Oncology Product Name: HMBD-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2021
Details:
Partnership will leverage Novogene’s strong molecular diagnostics capabilities to expand patient identification through Next Generation Sequencing, NGS, testing in China to support the development of Hummingbird Bioscience’s investigational drug candidate HMBD-001.
Lead Product(s): HMBD-001
Therapeutic Area: Oncology Product Name: HMBD-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Novogene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 09, 2021
Details:
Proceeds from the financing will be used to advance the clinical development of Hummingbird’s lead assets including, HMBD-001, a best-in-class HER3 antibody for NRG1-fusion and HER3-driven tumors, and HMBD-002, an anti-VISTA neutralizing antibody.
Lead Product(s): HMBD-001
Therapeutic Area: Oncology Product Name: HMBD-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novo Holdings
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 18, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
